PORTFOLIO
PORTFOLIO COMPANIES
Faraday Pharmaceuticals, Inc.
-
- Chief Executive Officer：
- Stephen A. Hill, M.D.
COMPANY PROFILE
Pioneering the use of specific, reduced forms of natural elements — elemental reducing agents — to improve quality of life after acute, critical illness.
Faraday Pharmaceuticals is focused on improving the quality of life for patients suffering from acute, critical illnesses. It was founded in 2014 based on the research of Dr. Mark Roth of the Fred Hutchinson Cancer Research Center.
Faraday’s product, FDY-5301, is being evaluated for its potential to minimize myocardial and skeletal muscle damage in acute illnesses. FDY-5301 contains sodium iodide as its active pharmaceutical ingredient, which regulates the strength and function of muscle tissue by catalytically breaking down hydrogen peroxide. In a Phase II trial, FDY-5301 has demonstrated its effectiveness on myocardial reperfusion injury associated with ST-Elevated Myocardial Infarction (STEMI) heart attack.
Faraday’s product, FDY-5301, is being evaluated for its potential to minimize myocardial and skeletal muscle damage in acute illnesses. FDY-5301 contains sodium iodide as its active pharmaceutical ingredient, which regulates the strength and function of muscle tissue by catalytically breaking down hydrogen peroxide. In a Phase II trial, FDY-5301 has demonstrated its effectiveness on myocardial reperfusion injury associated with ST-Elevated Myocardial Infarction (STEMI) heart attack.
COMPANY STORY
Origin
Faraday Pharmaceuticals was founded in 2014 based on the research of Dr. Mark Roth of the Fred Hutchinson Cancer Research Center, to improve the quality of life for patients suffering from acute, critical illnesses.
Strength
Faraday’s proprietary therapeutic, FDY-5301, has been shown to catalytically destroy hydrogen peroxide and is therefore uniquely differentiated from sacrificial anti-oxidants such as Vitamin C, providing a key advantage in the destruction of reactive oxygen species.
UTEC’s value add
UTEC supports Faraday in their academic collaborations, business development objectives, and handling regulatory affairs especially in Japan.
-
Infarct size assessed by cardiac magnetic resonance in a Phase 2 trial
